my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
ESBATech is a biopharmaceutical company focusing on therapeutic applications of its proprietary fully human antibody fragments. The company is aiming to become one of the leading companies in human antibody fragments for therapeutic applications. Antibody fragments are regarded as an attractive for more
OctoPlus N.V. announced that it has signed a contract with ESBATech, an Alcon Biomedical Research Unit, to develop a controlled release formulation for one of its proprietary biological compounds for ophthalmic applications.The project includes process development, scale-up and manufacturing for pre more
GENOVAC GmbH announced that they have entered into a research collaboration with ESBATech, an Alcon Biomedical Research Unit relative to the generation of antibodies for use in the field of ophthalmology. Under the terms of the agreement, GENOVAC will apply its proprietary genetic immunisation techn more
Alcon announced that it has entered into a definitive agreement to acquire ESBATech AG. Alcon will pay ESBATech shareholders $150 million in cash at closing, plus contingent payments of up to $439 million based upon the achievement of future research and development milestones that would be expecte more
OctoPlus N.V. (OctoPlus) operates as a drug delivery company, engaged in the development of improved pharmaceutical products. The company's business activities include formulation development services, drug delivery technologies and controlled release product development. It products portfolio inclu more
The Company Products & Technologies PR and Publications Career About ESBATech People Intellectual Property Directions Contact Drug Discovery Drug Development Company News Scientific Publications Upcoming Events PR Contact Why ESBATech Positions To apply Webmail ESBATech, an Alcon Biomedical Resear more
News Events Overview Rationale for Immunodrugs™ Strategy Board & Management Industry Collaborations Letter of the CEO History Overview Immunodrug™ Platform Immunodrug™ Manufacturing Scientific Collaborations Scientific Publications Pipeline Clinical Trials Disease Areas Overview Board & Management S more
The Company Products & Technologies PR and Publications Career Intellectual Property ESBATech’s products and technologies are patent protected. Earlier investments in the technology platforms have created significant value in the form of validated IP and generated a number of novel compounds i more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
